Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Ann Neurol. Author manuscript; available in PMC 2010 June 21.
Published in final edited form as:
PMCID: PMC2888285

Gender Differences in Pediatric Stroke: Is Elevated Testosterone a Risk Factor for Boys?

A recent advance in the field of stroke is the understanding that it is a sexually dimorphic disease, that is, outcomes and disease mechanisms are influenced by the individual’s biological sex. The overall incidence of stroke is higher in men versus women in most nations, a trend that cuts across ethnic background.1 This sexually dimorphic epidemiology extends well beyond the menopausal years and is clearly present in young children.25 For example, stroke incidence as estimated from a state-wide hospital discharge database emphasize that boys carry higher risk for all stroke types than do girls.2 Boys also have a higher case fatality rate for ischemic, but not hemorrhagic, stroke than do girls in this same report. In the International Pediatric Stroke Study, ischemic stroke is more common in boys, regardless of age, trauma history, or stroke subtype.3

There is also a suggestion that stroke outcome, like risk, is influenced by sex or sex in combination with age. In aggregate, animal studies predominately in young adult rodents have demonstrated that males sustain greater histological damage after experimental stroke than females. However, in humans and aging animals, infarction size and functional outcome after cerebral ischemia can paradoxically be worse in females than in their male counterparts (for reviews, see Hurn et al,6 Herson et al,7 Reeves et al,8 and Liu et al9). Furthermore, cellular and molecular death mechanisms are not always identical in the male versus female brain or in XX versus XY cell cultures (for a recent review, see Cheng and Hurn10). Examples of molecules that have sexually dimorphic roles in cerebral ischemic injury mechanisms include apoptosis-inducing factor, caspase 8, poly-adenosine diphosphate ribose polymerase, nitric oxide synthase, glutathione, Akt, astrocytic aromatase, glial fibrillary acidic protein, angiotensin II type 2 receptor, and the P450 enzyme, soluble epoxide hydrolase. Such studies emphasize the importance of biological sex yet do not discount the importance of gonadal sex steroids or brain-derived neurosteroids as modulators of oxidant, toxic, and ischemic challenges to the brain. The vast majority of this information has come from in vivo studies of gonadally intact or castrated adult animals with or without hormonal replacement, as well as in vitro studies that remove specimens from circulating hormones.

We know very little about these factors in pediatric stroke. In this issue of Annals of Neurology, Normann et al provide provocative evidence that the male child’s risk for arterial ischemic stroke or cerebral sinovenous thrombosis is linked to androgen availability.11 Specifically, elevated plasma levels (>90th percentile for age and gender) of the principal circulating androgen, testosterone, were found to be associated with a 4–5-fold increased risk of cerebrovascular disease after adjustment for pubertal status, cholesterol, and hematocrit. Furthermore, among the boys, there was a dose–response relationship such that for each 1nmol/l increase in testosterone level, the odds of stroke were increased. This novel finding is the first to address androgens in pediatric stroke and is consistent with the rather sparse literature that androgens impact ischemic outcomes and mechanisms of brain damage.7,1216 In contrast, low circulating testosterone levels are associated with higher stroke incidence and worse outcomes after stroke in men.1216 Importantly, androgen levels dramatically drop after both experimental and clinical stroke in adults.1416 In experimental studies that control pre- and postischemic androgen levels, androgens can reduce or exacerbate ischemic damage, further confusing the issue.16,17 In the study by Normann et al,11 testosterone levels were measured in cases 6 to 12 months after the ischemic event and assumed to reflect prior circulating levels and thus risk. However, regardless of this limitation, it is clear that further clinical and experimental studies are necessary to understand the involvement of circulating androgens in pediatric stroke.


Potential conflict of interest: Nothing to report.

Contributor Information

Susan J. Vannucci, Department of Pediatrics/Newborn Medicine, Weill Cornell Medical College, New York, NY.

Patricia D. Hurn, Departments of Anesthesiology and Perioperative Medicine, Physiology, and Neurology Orgenon Health Science University Portland, OR.


1. Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. International Stroke Incidence Collaboration. Stroke. 1997;28:491–499. [PubMed]
2. Fullerton HJ, Wu YW, Zhao S, Johnston SC. Risk of stroke in children. Neurol. 2003;61:189–194. [PubMed]
3. Golomb MR, Fullerton HJ, Nowak-Gottl U, Deveber G. International Pediatric Stroke Study Group. Male predominance in childhood ischemic stroke: findings from the international pediatric stroke study. Stroke. 2009;40:52–57. [PubMed]
4. Golomb MR, Dick PT, MacGregor DL, Curtis R, Sofronas M, deVeber GA. Neonatal arterial ischemic stroke and cerebral sinovenous thrombosis are more commonly diagnosed in boys. J Child Neurol. 2004;19:493–498. [PubMed]
5. Lo W, Stephens J, Fernandez S. Pediatric stroke in the United States and the impact of risk factors. J Child Neurol. 2009;24:194–203. [PMC free article] [PubMed]
6. Hurn PD, Vannucci SJ, Hagberg H. Adult or perinatal brain injury: does sex matter? Stroke. 2005;36:193–195. [PubMed]
7. Herson PS, Koerner IP, Hurn PD. Sex, sex steroids, and brain injury. Semin Reprod Med. 2009;27:229–239. [PMC free article] [PubMed]
8. Reeves MJ, Bushnell CD, Howard G, et al. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol. 2008;7:915–926. [PMC free article] [PubMed]
9. Liu F, Yuan R, Benashski SE, McCullough LD. Changes in experimental stroke outcome across the life span. J Cereb Blood Flow Metab. 2009;29:792–802. [PMC free article] [PubMed]
10. Cheng J, Hurn PD. Sex shapes experimental brain injury. Steroids. (in press)
11. Normann S, de Veber G, Fobker M, et al. Role of endogenous testosterone concentration in pediatric stroke. Ann Neurol. 2010;00:000–000.
12. Yeap BB, Hyde Z, Almeida OP, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab. 2009;94:2353–2359. [PubMed]
13. Hollander M, Koudstaal PJ, Bots ML, et al. Incidence, risk, and case fatality of first ever stroke in the elderly population. The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2003;74:317–321. [PMC free article] [PubMed]
14. Jeppesen LL, Jorgensen HS, Nakayama H, et al. Decreased serum testosterone in men with acute ischemic stroke. Arterioscler Thromb Vasc Biol. 1996;16:749–754. [PubMed]
15. Dash RJ, Sethi BK, Nalini K, Singh S. Circulating testosterone in pure motor stroke. Funct Neurol. 1991;6:29–34. [PubMed]
16. Uchida M, Palmateer JM, Herson PS, et al. Dose-dependent effects of androgens on outcome after focal cerebral ischemia in adult male mice. J Cereb Blood Flow Metab. 2009;29:1454–1462. [PMC free article] [PubMed]
17. Yang SH, Perez E, Cutright J, et al. Testosterone increases neurotoxicity of glutamate in vitro and ischemia-reperfusion injury in an animal model. J Appl Physiol. 2002;92:195–201. [PubMed]